Is gabapentin appropriate for treating anxiety, and what dosing regimen and monitoring are recommended?

Gabapentin for Anxiety: Clinical Recommendation

Gabapentin is not recommended as a first-line treatment for generalized anxiety disorders, but may be considered as a second- or third-line option for specific anxiety conditions, particularly social anxiety disorder and severe panic disorder, after standard therapies have failed. 1, 2

Evidence Quality and Context

The available evidence for gabapentin in anxiety is limited and context-specific:

• No major psychiatric guidelines recommend gabapentin as first-line therapy for anxiety disorders 1
• The NICE guidelines for anxiety management recommend benzodiazepines (lorazepam 0.5-1 mg orally four times daily) as the standard anxiolytic approach, not gabapentin 1
• Evidence supports gabapentin primarily for social anxiety disorder and severe panic disorder as third-line options after SSRIs/SNRIs and benzodiazepines 2

When Gabapentin May Be Appropriate

Consider gabapentin for anxiety only in these specific scenarios:

• Social anxiety disorder with inadequate response to SSRIs/SNRIs, where studies showed significant symptom reduction at doses of 900-3600 mg/day 3
• Severe panic disorder (baseline Panic and Agoraphobia Scale score ≥20), where post-hoc analysis demonstrated benefit 4
• Preoperative anxiety, where gabapentin 1200 mg single dose significantly reduced anxiety compared to placebo and hydroxyzine 5
• Breast cancer survivors with anxiety, where both 300 mg and 900 mg daily showed efficacy, with lower doses (300 mg) associated with best outcomes except in highest baseline anxiety 6

Dosing Regimen

When prescribing gabapentin for anxiety:

• Starting dose: 300 mg once daily at bedtime 7
• Titration: Increase by 300 mg every 1-7 days as tolerated 7
• Target dose range: 900-3600 mg/day in three divided doses 3, 2
• Optimal dosing: Most studies used 900-1800 mg/day for anxiety conditions 6, 3
• Maximum interval between doses: Should not exceed 12 hours 8

Renal Dosing Adjustments

Mandatory dose reduction in renal impairment 8:

• CrCl 30-59 mL/min: 200-700 mg twice daily
• CrCl 15-29 mL/min: 200-700 mg once daily
• CrCl <15 mL/min: 100-300 mg once daily
• Hemodialysis: Maintenance dose based on CrCl plus supplemental 125-350 mg post-dialysis 8

Monitoring Requirements

Essential monitoring parameters:

• Baseline assessment: Screen for history of opioid or prescription drug abuse before prescribing, as gabapentin carries abuse potential particularly in this population 9
• Dose-dependent side effects: Dizziness, sedation, and somnolence occur commonly and can be minimized by slow titration 7
• Renal function: Check creatinine clearance before initiating and adjust dosing accordingly 8
• Concurrent medications: Particularly important to identify concurrent opioid use, which significantly increases mortality risk 10

Critical Safety Concerns

Important caveats that limit gabapentin's role in anxiety:

• Rising mortality rates: Deaths involving pregabalin (a related gabapentinoid) now exceed those from diazepam, with 244 deaths recorded in 2019, usually involving concomitant opioid use 10
• Tolerance and dependence: Gabapentinoids share similar issues with benzodiazepines regarding tolerance, dependence, addiction, and withdrawal 10
• Controlled substance status: Gabapentinoids were scheduled as class C controlled drugs in 2019 due to abuse risks 10
• Limited long-term data: Evidence derives from short-term trials with marginal differences from placebo, not accounting for longer-term tolerance, dependence, and withdrawal effects 10

Discontinuation Protocol

Gradual taper is mandatory:

• Reduce dose gradually over minimum of 1 week (longer periods may be needed at prescriber's discretion) 8
• Abrupt discontinuation should be avoided due to withdrawal syndrome risk 10

Why Not First-Line?

The evidence clearly demonstrates that SSRIs/SNRIs remain superior first-line options:

• Duloxetine (30-60 mg daily) has proven efficacy in generalized anxiety disorder with straightforward dosing 7
• Venlafaxine (150-225 mg daily) shows consistent benefit across anxiety conditions 7
• These agents have more robust evidence, better safety profiles, and established guidelines supporting their use 1, 11

Gabapentin should be reserved for patients who have failed or cannot tolerate standard anxiolytic therapies, with careful consideration of abuse potential and concurrent substance use. 2, 9